Research > Focus D > Work Packages D04
By drawing a multidimensional map of therapy resistance, UNITE aims to develop concepts to predict and monitor treatment response and failure, and ultimately, to discover novel (combination) therapies for glioblastoma patients.
To understand initiation, progression and therapy resistance of glioblastomas at a molecular basis of patient-derived tissues, we are in the process of building a UNITE core collection consisting of 100 glioblastoma samples for which we will establish a uniform data matrix, consisting of epigenome analysis, whole-genome sequencing, RNA sequencing, single cell sequencing, data on a set of currently relevant biomarkers, and metabolomics and proteomic profiling. For selected samples, MRI imaging data obtained from tumors in patients and mice after xenogeneic transplantation (PDX) as well as clinical data will be integrated. The core collection will be built from selected samples from all UNITE WPs. Additional data on genetic or pharmacological manipulation or analysis of recurrent / progressive tumors will be integrated from work in individual WPs.
